Amphastar Pharmaceuticals, Inc. AMPH
Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) is a cardio-renal-metabolic specialty pharmaceutical company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Biosimilar insulin candidate (BLA on file) | Diabetes | protein/peptide | Phase 3 |
| Generic ANDA on file with FDA | — | small molecule | Phase 3 |
| Proprietary / inhalation product candidates (insulin and inhalation pipeline, clinical trials ongoing) | — | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.